It is accepted that patients with pancreatic cancer are best treated by a combination of surgical resection and systemic chemotherapy; the optimal sequence remains debated.
There are ongoing trials on survival benefit of neoadjuvant therapy (NAT) compared to upfront surgery (UFS) in patients with resectable and borderline resectable pancreatic cancer; new and updated data must be analyzed for continued understanding of results.
